Abstract:Background: Hemophilia B is a bleeding disorder caused by defective factor IX (FIX), currently treated by regular infusions of plasma-derived or recombinant FIX. We propose a gene therapy strategy based on the implantation of cells secreting FIX enclosed in alginate microcapsules as a highly desirable alternative treatment. We have reported sustained delivery of human factor IX (hFIX) in immunocompetent mice implanted with encapsulated primary mouse myoblasts engineered to secrete hFIX. As a step towards the treatment of human patients, in this study we report the implantation of encapsulated human primary myoblasts secreting hFIX in hemophilia B mice. Methods: Human primary myoblasts were transfected with plasmids pKL4M-hFIX, pLNM-betaIXL, pMFG-hFIX, and transduced with retrovirus MFG-hFIX. Two human primary myoblast clones secreting approximately 1 microg hFIX/10(6) cells/day were enclosed in biocompatible alginate microcapsules and implanted intraperitoneally into SCID and hemophilic mice. Results: Circulating hFIX (peak of approximately 120 ng/ml) was detected in hemophilia B mice on day 1 after implantation. Human FIX delivery was transient, however, becoming undetectable on day 14. Concurrently, anti-hFIX antibodies were detected. At the same time, activated partial thromboplastin time (APTT) was reduced from 94 s before treatment to 78-80 s. Tail bleeding time decreased from 15 min to 1.5-7 min after treatment, some mice being normalised. These findings indicate that the delivered hFIX is biologically active. Similarly treated NOD/SCID mice had circulating hFIX levels of 170 ng/ml on day 1 that remained detectable for 1 month, albeit at low levels. Cell viability of microcapsules retrieved on day 60 was below 5%. Conclusions: Our findings indicate that encapsulated human primary myoblasts secrete functional hFIX. Furthermore, implantation of encapsulated human primary myoblasts can partially correct the phenotype of hemophilia B mice, supporting the feasibility of this gene therapy approach for hemophilia B. However, the long-term viability of the encapsulated human myoblasts must first be improved.

Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice

Implantation of Autologous Skin Fibroblast Genetically Modified to Secrete Clotting Factor Ix Partially Corrects the Hemorrhagic Tendencies in Two Hemophilia B Patients

[Human coagulation factor IX gene therapy in murine hemophilia B by hydrodynamic delivery and site-specific genomic integration]

High Expression of Human Clotting Factor Ix Cdna in Myoblasts C2c12 Cells and C3h Mice

Gene Therapy for Hemophilia B Mice with Scaav8-Lp1-hfix

Engraftment of Genetically Modified Human Amniotic Fluid‐derived Progenitor Cells to Produce Coagulation Factor IX after in Utero Transplantation in Mice

Gene Therapy for Hemophilia B Mediated by Recombinant Adeno-Associated Viral Vector with Hfixr338a,a High Catalytic Activity Mutation of Human Coagulation Factor IX

Efficient Transfer and Expression of Human Clotting Factor IX Cdna in Neonatal Hemophilia B Mice Mediated by VSV-G Pseudotyped Retrovirus

Expression Of Human Factor Ix Gene In Murine Plasma Through Lentiviral Vector-Infected Haematopoietic Stem Cells

Muscle Injection of Raav/mfix to Secrete Clotting Factor IX Corrects the Hemorrhagic Tendencies in Hemophilia B Mice

Skeletal Muscle-Specific Expression of Human Blood Coagulation Factor IX Rescues Factor IX Deficiency Mouse by AAV-mediated Gene Transfer.

Stage I Clinical Trial of Gene Therapy for Hemophilia B.

Gene Therapy for Hemophilia B in Immature Mice Using ScAAV-DJ/8-LP1-hFIXco Vector

Sustaining Expression of B Domain-Deleted Human Factor VIII Mediated by Using Lentiviral Vectors in NOD/SCID Mouse.

Optimized Human Factor IX Expression Cassettes for Hepatic-Directed Gene Therapy of Hemophilia B

High Expression of Human Clotting Factor-Ix Cdna in the Bone-Marrow Stroma Cells of Hemophilia-B Patient

Gene Therapy for Hemophilia B with Liver-specific Element Mediated by Rep-RBE Site-specific Integration System

Long-term Correction of Hemophilia B Through CRISPR/Cas9 Induced Homology-Independent Targeted Integration

Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse

[Preparation of Raav2/hfix and Experimentally Application to Gene Therapy for Hemophilia B].

CRISPR-Cas9-Mediated in Vivo Gene Integration at the Albumin Locus Recovers Hemostasis in Neonatal and Adult Hemophilia B Mice.